Federated Hermes, Inc. Kiniksa Pharmaceuticals, Ltd. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $54,983 - $80,173	-5,292 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.39 - $16.23 $56,255 - $80,159	4,939 Added 1399.15%	5,292 $60,000
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $3,186 - $4,600	-241 Reduced 40.57%	353 $5,000
Q4 2020 Feb 12, 2021	SELL	$14.8 - $21.15 $6.1 Million - $8.71 Million	-411,839 Reduced 99.86%	594 $10,000
Q3 2020 Nov 12, 2020	BUY	$15.21 - $25.53 $248,120 - $416,470	16,313 Added 4.12%	412,433 $6.32 Million
Q2 2020 Aug 13, 2020	BUY	$15.08 - $26.0 $2.73 Million - $4.71 Million	181,021 Added 84.16%	396,120 $10.1 Million
Q1 2020 May 13, 2020	BUY	$11.0 - $19.76 $2.37 Million - $4.25 Million	215,099 New	215,099 $3.33 Million

1.99M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $752M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.